2026 Q2 - tulosraportti
Vain PDF
41 päivää sitten
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 378 | - | - | ||
| 1 030 | - | - | ||
| 470 | - | - | ||
| 835 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 25.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·3 t sittenI think Sprint is really interesting long-term. Unlike other biotech companies that normally focus on a few candidates, Sprint has its edge in the platform. Previously, Sprint only worked on licensing out its candidates, but a little over a year ago they broadened the model to include platform collaborations. Meaning making the deal before producing the candidate where the counterparty decides the target. I talked to the CSO when I was at Sprint's annual meeting and asked about their capacity. He stated that their current capacity is that they can build 5 candidates in parallel with a completion time of 1-2 years. This with the current burn rate of ≈ 5msek/month. If you look at similar agreements signed for other companies, an upfront of 5-10 musd/project is not unreasonable. Should Sprint land an agreement in that interval that consumes the entire capacity, it alone would cover the annual costs several times over. Then milestones/royalties will quickly pile up. The big question mark is 1) is the company's platform attractive enough to land commitments. 2) What can they charge. In the CEO's address for the Q3 report 2025, Johan wrote: “Otherwise, the past quarter was characterized by discussions regarding collaborations linked to our platform for fragment-based drug discovery. Broadening the revenue base through platform collaborations is a central part of our strategy. At BIOEurope in Vienna in November, we encountered a clear interest from companies wanting to explore opportunities for strategic collaborations, an attractive way for us to create new revenue streams.” About a year has passed, which is a normal timeline for these types of agreements. Time to deliver for the company in the coming months. If they land something here, I believe the upside is really big. And this completely excluding the agreement with Gilead worth up to 400musd + 5 partner-ready projects in the pipeline + undisclosed
·30.9.Now I have repurchased my position, after having the money parked in Nanexa for a moment. It will probably be a long-term parking. 
Agree, have most in Sprint now but will have both Nanexa and Alzecure in my portfolio later. Only work with biotech that has active deals with milestones and cash in the bank. Phase 2 companies without deals and expensive studies are completely out. Sprint is still valued unreasonably low with potentially 4 billion SEK from Gilead in milestones and 2-3 programs ready for deals. Gilead and Lilly (tunelab) have done due diligence on Sprint and seem to like what they saw, "retail investors" are sleeping (2300 owners on Avanza says a lot).
·29.9.Sprint Bioscience has broken out of the falling trend channel. The stock has broken a resistance level and given a buy signal. The stock is approaching support at approximately 2.74 kronor, which could provide an upward reaction. 📈🚀
- ·28.8.I still think there's a strange mismatch between the words in the report and the news flow. The report states: The CEO has the word During the second quarter, great effort was put into BIO International, the world's largest partnering conference, which was carried out with very good results. And then half a page is used to tell how well it went at BIO, while there has been no news about anything concrete. I think it is strongly suggested that something will happen with either NNMT or VRK1 in the near future, and that it will be big. However, I must say that I hope it only happens later in the year, as I have reduced my Sprint position to buy a larger speculative position in Nanexa which I hope and believe will land a deal first. But then I also need to convert that profit back to Sprint.
·26.8.I have held Sprint Bioscience since 08.01.2026, and they have never let me down. I believe there is still a lot of potential.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 62 024 | 62 024 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 62 024 | 62 024 | 0 | 0 |
2026 Q2 - tulosraportti
Vain PDF
41 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenI think Sprint is really interesting long-term. Unlike other biotech companies that normally focus on a few candidates, Sprint has its edge in the platform. Previously, Sprint only worked on licensing out its candidates, but a little over a year ago they broadened the model to include platform collaborations. Meaning making the deal before producing the candidate where the counterparty decides the target. I talked to the CSO when I was at Sprint's annual meeting and asked about their capacity. He stated that their current capacity is that they can build 5 candidates in parallel with a completion time of 1-2 years. This with the current burn rate of ≈ 5msek/month. If you look at similar agreements signed for other companies, an upfront of 5-10 musd/project is not unreasonable. Should Sprint land an agreement in that interval that consumes the entire capacity, it alone would cover the annual costs several times over. Then milestones/royalties will quickly pile up. The big question mark is 1) is the company's platform attractive enough to land commitments. 2) What can they charge. In the CEO's address for the Q3 report 2025, Johan wrote: “Otherwise, the past quarter was characterized by discussions regarding collaborations linked to our platform for fragment-based drug discovery. Broadening the revenue base through platform collaborations is a central part of our strategy. At BIOEurope in Vienna in November, we encountered a clear interest from companies wanting to explore opportunities for strategic collaborations, an attractive way for us to create new revenue streams.” About a year has passed, which is a normal timeline for these types of agreements. Time to deliver for the company in the coming months. If they land something here, I believe the upside is really big. And this completely excluding the agreement with Gilead worth up to 400musd + 5 partner-ready projects in the pipeline + undisclosed
- ·30.9.Now I have repurchased my position, after having the money parked in Nanexa for a moment. It will probably be a long-term parking. Agree, have most in Sprint now but will have both Nanexa and Alzecure in my portfolio later. Only work with biotech that has active deals with milestones and cash in the bank. Phase 2 companies without deals and expensive studies are completely out. Sprint is still valued unreasonably low with potentially 4 billion SEK from Gilead in milestones and 2-3 programs ready for deals. Gilead and Lilly (tunelab) have done due diligence on Sprint and seem to like what they saw, "retail investors" are sleeping (2300 owners on Avanza says a lot).
- ·29.9.Sprint Bioscience has broken out of the falling trend channel. The stock has broken a resistance level and given a buy signal. The stock is approaching support at approximately 2.74 kronor, which could provide an upward reaction. 📈🚀
- ·28.8.I still think there's a strange mismatch between the words in the report and the news flow. The report states: The CEO has the word During the second quarter, great effort was put into BIO International, the world's largest partnering conference, which was carried out with very good results. And then half a page is used to tell how well it went at BIO, while there has been no news about anything concrete. I think it is strongly suggested that something will happen with either NNMT or VRK1 in the near future, and that it will be big. However, I must say that I hope it only happens later in the year, as I have reduced my Sprint position to buy a larger speculative position in Nanexa which I hope and believe will land a deal first. But then I also need to convert that profit back to Sprint.
- ·26.8.I have held Sprint Bioscience since 08.01.2026, and they have never let me down. I believe there is still a lot of potential.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 378 | - | - | ||
| 1 030 | - | - | ||
| 470 | - | - | ||
| 835 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 25.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 62 024 | 62 024 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 62 024 | 62 024 | 0 | 0 |
2026 Q2 - tulosraportti
Vain PDF
41 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 11.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 13.5. | ||
2025 Q4 - tulosraportti 11.2. | ||
2025 Q3 - tulosraportti 25.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sittenI think Sprint is really interesting long-term. Unlike other biotech companies that normally focus on a few candidates, Sprint has its edge in the platform. Previously, Sprint only worked on licensing out its candidates, but a little over a year ago they broadened the model to include platform collaborations. Meaning making the deal before producing the candidate where the counterparty decides the target. I talked to the CSO when I was at Sprint's annual meeting and asked about their capacity. He stated that their current capacity is that they can build 5 candidates in parallel with a completion time of 1-2 years. This with the current burn rate of ≈ 5msek/month. If you look at similar agreements signed for other companies, an upfront of 5-10 musd/project is not unreasonable. Should Sprint land an agreement in that interval that consumes the entire capacity, it alone would cover the annual costs several times over. Then milestones/royalties will quickly pile up. The big question mark is 1) is the company's platform attractive enough to land commitments. 2) What can they charge. In the CEO's address for the Q3 report 2025, Johan wrote: “Otherwise, the past quarter was characterized by discussions regarding collaborations linked to our platform for fragment-based drug discovery. Broadening the revenue base through platform collaborations is a central part of our strategy. At BIOEurope in Vienna in November, we encountered a clear interest from companies wanting to explore opportunities for strategic collaborations, an attractive way for us to create new revenue streams.” About a year has passed, which is a normal timeline for these types of agreements. Time to deliver for the company in the coming months. If they land something here, I believe the upside is really big. And this completely excluding the agreement with Gilead worth up to 400musd + 5 partner-ready projects in the pipeline + undisclosed
- ·30.9.Now I have repurchased my position, after having the money parked in Nanexa for a moment. It will probably be a long-term parking. Agree, have most in Sprint now but will have both Nanexa and Alzecure in my portfolio later. Only work with biotech that has active deals with milestones and cash in the bank. Phase 2 companies without deals and expensive studies are completely out. Sprint is still valued unreasonably low with potentially 4 billion SEK from Gilead in milestones and 2-3 programs ready for deals. Gilead and Lilly (tunelab) have done due diligence on Sprint and seem to like what they saw, "retail investors" are sleeping (2300 owners on Avanza says a lot).
- ·29.9.Sprint Bioscience has broken out of the falling trend channel. The stock has broken a resistance level and given a buy signal. The stock is approaching support at approximately 2.74 kronor, which could provide an upward reaction. 📈🚀
- ·28.8.I still think there's a strange mismatch between the words in the report and the news flow. The report states: The CEO has the word During the second quarter, great effort was put into BIO International, the world's largest partnering conference, which was carried out with very good results. And then half a page is used to tell how well it went at BIO, while there has been no news about anything concrete. I think it is strongly suggested that something will happen with either NNMT or VRK1 in the near future, and that it will be big. However, I must say that I hope it only happens later in the year, as I have reduced my Sprint position to buy a larger speculative position in Nanexa which I hope and believe will land a deal first. But then I also need to convert that profit back to Sprint.
- ·26.8.I have held Sprint Bioscience since 08.01.2026, and they have never let me down. I believe there is still a lot of potential.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 378 | - | - | ||
| 1 030 | - | - | ||
| 470 | - | - | ||
| 835 | - | - | ||
| 25 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 62 024 | 62 024 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 62 024 | 62 024 | 0 | 0 |